Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,088 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rescue combination treatment of anti-MDA5-associated ARDS with daratumumab.
Ostendorf L, Muench F, Thormählen L, Galbavý Z, Körner R, Nee J, Schneider U. Ostendorf L, et al. Among authors: schneider u. RMD Open. 2023 Jul;9(3):e003238. doi: 10.1136/rmdopen-2023-003238. RMD Open. 2023. PMID: 37479497 Free PMC article. No abstract available.
Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus.
Ostendorf L, Burns M, Durek P, Heinz GA, Heinrich F, Garantziotis P, Enghard P, Richter U, Biesen R, Schneider U, Knebel F, Burmester G, Radbruch A, Mei HE, Mashreghi MF, Hiepe F, Alexander T. Ostendorf L, et al. Among authors: schneider u. N Engl J Med. 2020 Sep 17;383(12):1149-1155. doi: 10.1056/NEJMoa2023325. N Engl J Med. 2020. PMID: 32937047
Evaluation of SIGLEC1 in the diagnosis of suspected systemic lupus erythematosus.
Zorn-Pauly L, von Stuckrad ASL, Klotsche J, Rose T, Kallinich T, Enghard P, Ostendorf L, Burns M, Doerner T, Meisel C, Schneider U, Unterwalder N, Burmester G, Hiepe F, Alexander T, Biesen R. Zorn-Pauly L, et al. Among authors: schneider u. Rheumatology (Oxford). 2022 Aug 3;61(8):3396-3400. doi: 10.1093/rheumatology/keab875. Rheumatology (Oxford). 2022. PMID: 34849605
SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies.
Graf M, von Stuckrad SL, Uruha A, Klotsche J, Zorn-Pauly L, Unterwalder N, Buttgereit T, Krusche M, Meisel C, Burmester GR, Hiepe F, Biesen R, Kallinich T, Stenzel W, Schneider U, Rose T. Graf M, et al. Among authors: schneider u. RMD Open. 2022 Feb;8(1):e001934. doi: 10.1136/rmdopen-2021-001934. RMD Open. 2022. PMID: 35177553 Free PMC article.
Tocilizumab treatment for polyarteritis nodosa.
Krusche M, Ruffer N, Schneider U, Meyer M, Burmester G, Kötter I. Krusche M, et al. Among authors: schneider u. Rheumatology (Oxford). 2020 Oct 1;59(10):e63-e65. doi: 10.1093/rheumatology/keaa079. Rheumatology (Oxford). 2020. PMID: 32182367 No abstract available.
1,088 results